rs7047299 — IFNA21

IFNA21 rs7047299 — When Your Innate Antiviral Defense Runs Quiet

Herpes zoster — shingles — is not a new infection. It is varicella-zoster virus (VZV) waking up after decades of dormancy in your dorsal root ganglia, the nerve cell clusters flanking your spinal cord. Almost everyone who had chickenpox as a child carries the virus for life. Whether it stays dormant or breaks through depends critically on how well your immune system — and specifically your type I interferon¹¹ type I interferon
A family of cytokines (IFN-alpha and IFN-beta) released within hours of viral detection; they trigger antiviral gene expression in neighboring cells, resist viral replication, and prime adaptive immune responses response — patrols the territory. rs7047299 sits upstream of IFNA21, one of thirteen interferon alpha genes clustered on chromosome 9p21.3, and the A allele at this position is associated with greater susceptibility to shingles.

The Mechanism

IFNA21 encodes interferon alpha-21²² interferon alpha-21
One of 13 IFNA genes clustered on chromosome 9p21.3 encoding subtly distinct IFN-alpha protein isoforms with overlapping but non-identical antiviral potencies; the cluster evolved through repeated gene duplications, a type I interferon secreted primarily by plasmacytoid dendritic cells within hours of detecting viral DNA via TLR9 and other innate sensors. rs7047299 lies approximately 800 bp upstream of the IFNA21 transcription start site — within the proximal promoter/regulatory region — and is annotated as a 2 KB upstream regulatory variant.

Two independent lines of experimental work establish why this matters specifically for VZV. First, IFN-alpha from epidermal cells is the primary barrier to VZV skin spread³³ IFN-alpha from epidermal cells is the primary barrier to VZV skin spread
Blocking IFN-alpha receptor in ex vivo human skin increased VZV viral titers approximately tenfold; VZV itself down-regulates IFN-alpha in infected cells to enable focal replication while neighboring uninfected cells still mount a response. Second, IFN-alpha signals through the IFN-α–IRF9 axis⁴⁴ IFN-alpha signals through the IFN-α–IRF9 axis
IRF9 is an interferon regulatory factor induced by IFN-alpha signaling; it forms the ISGF3 transcription complex that activates hundreds of interferon-stimulated genes; VZV's IE62 protein transcriptionally suppresses IRF9 to escape this response as the first-line delay mechanism against VZV replication. A regulatory variant that reduces IFNA21 promoter activity — or alters expression timing — would blunt this initial barrier, giving the virus an earlier window to replicate before adaptive T cell immunity is mobilized.

The Evidence

The primary association comes from a [large multi-infection GWAS | 23 GWAS studies across

200,000 individuals of European ancestry tested for 23 common infections simultaneously; 59 genome-wide significant loci identified; designed to identify immune-genetic contributions using 23andMe participant cohort data](https://pubmed.ncbi.nlm.nih.gov/28928442/⁵⁵ https://pubmed.ncbi.nlm.nih.gov/28928442/) by Tian et al. (2017), which identified rs7047299 as a genome-wide significant hit for shingles susceptibility (OR = 1.07; 95% CI, 1.06–1.09; p = 2 × 10⁻⁸). The variant maps to the IFNA21/IFNWP15 chromosomal region, and the biological link to interferon-alpha production is mechanistically coherent. The per-allele OR of 1.07 is modest — comparable to many common GWAS risk alleles — but the genome-wide significance threshold provides high confidence that the association is real, not a false positive.

Complementary human evidence comes from patients with autoimmune polyendocrine syndrome type 1 (APS-1)⁶⁶ patients with autoimmune polyendocrine syndrome type 1 (APS-1)
APS-1 patients produce high-titer neutralizing autoantibodies against IFN-alpha; this natural human experiment allows researchers to observe the effect of IFN-alpha deficiency on infection susceptibility in a live clinical setting, who produce neutralizing autoantibodies against IFN-alpha and experience significantly higher rates of VZV reactivation — directly confirming that inadequate IFN-alpha signaling is sufficient to allow VZV to break through. These patients also show decreased humoral responses to VZV specifically, pointing to IFN-alpha's role in coordinating both innate and adaptive antiviral defenses.

The evidence level is moderate: the GWAS association is large-scale and genome-wide significant, the biological mechanism is experimentally established, but the specific functional impact of rs7047299 on IFNA21 expression has not been characterized in an eQTL study, and dose-response data for AA vs. AG vs. GG carriers are not available from the 2017 paper.

Practical Actions

The most directly actionable implication of carrying one or two copies of the A allele is that your innate antiviral response to VZV reactivation may be somewhat blunted — not absent, but operating at reduced efficiency. Shingrix (recombinant zoster vaccine, RZV) is specifically designed to compensate for this by building strong T cell memory against VZV glycoprotein E with its AS01B adjuvant system, achieving [≥90% efficacy against herpes zoster | ZOE-70 trial:

90% efficacy in adults 70+; ZOE-50 trial: 97.2% efficacy in adults 50–69; pooled long-term data show efficacy remains high at 10+ years post-vaccination](https://pubmed.ncbi.nlm.nih.gov/27626517/⁷⁷ https://pubmed.ncbi.nlm.nih.gov/27626517/) even when innate immune responses decline with age. Prioritizing Shingrix vaccination at the earliest eligible age (50 in most guidelines) is the highest-yield intervention.

Beyond vaccination, supporting robust IFN-alpha production involves avoiding immunosuppressive medications that explicitly block interferon signaling (JAK inhibitors, high-dose corticosteroids) when alternatives exist, and discussing shingles prophylaxis with your physician before starting any such treatments.

Interactions

The IFNA gene cluster on 9p21.3 contains thirteen IFNA genes in close proximity. Variants in neighboring interferon genes — particularly those affecting the broader interferon locus haplotype — may compound or buffer the effect of rs7047299. The IFNL3/IFNL4 locus on chromosome 19 (rs11322783, rs12979860) encodes type III interferons (lambda interferons) that act through a parallel pathway targeting epithelial cells; individuals with reduced type III interferon function alongside reduced type I interferon from rs7047299 may have broader antiviral vulnerability. Compound actions for this combination have not been studied, but the convergence of reduced innate signaling across multiple interferon families represents a biologically plausible interaction.